Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Published: October 20, 2021 at 03:56PM
from NYT Health https://ift.tt/3AZ0ZG8